As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

Sales of heart failure medication Entresto fell short of expectations, while closely watched cancer drug Pluvicto only beat estimates because of a one-time gain. The results pushed Novartis shares ...

It’s easier for the heart to pump blood into relaxed blood ... They each belong to a different group of drugs. Entresto and Verquvo interact with different drugs. For example, Entresto interacts ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

Verquvo (vericiguat) is a brand-name oral tablet that’s prescribed to help prevent complications from heart failure. As with other drugs, Verquvo can cause side effects. These include low blood ...

Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...